Alzheimer's Disease and Dementia
Featured Topics
Lead story
Other featured articles
-
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for future advances in Alzheimer’s disease (AD) made in 2001 and projects future breakthroughs over the next 20 years.
Posted in -
The Value of Delaying Alzheimer’s Disease Onset
Models show that the number of patients will more than double in 40 years, and costs associated with their care will nearly quintuple.
Posted in -
2023 Clinical Trial Recruitment Lab (CTRL) Request for Pilot Project Proposals
CTRL is seeking proposals for pilot projects that test strategies and solutions designed to address barriers to recruitment for Alzheimer’s disease clinical trials.
Posted in -
Social and Biomedical Scientists Come Together to Address the Burden of Alzheimer’s Disease
Social scientists are uniquely poised to evaluate the implications of Alzheimer’s costs, yet they often lack knowledge of the biomedical foundations of the disease.
Posted in
About this section
Even small delays in the onset of Alzheimer's disease and dementia could have significant impacts for the patient, their family and caregivers, and the healthcare system more broadly. The Schaeffer Center's microsimulation models demonstrate there may be preventive measures we can take now to shape the nation's future health.
OUR EXPERTS ON ALZHEIMER'S DISEASE AND DEMENTIA PREVENTION
Our Work In Alzheimer's Disease and Dementia
-
CMS’s Alzheimer’s Coverage Policy Will Inhibit Access and Discourage Innovation
Individuals in underserved communities have to travel long distances, well beyond the 30-minute standard, to access clinical trial sites for Aduhelm.
Categorized in -
Interdisciplinary Panel Offers Solutions to Improve Recruitment for Alzheimer’s Clinical Trials
Experts from the private and public sectors convened a panel to improve recruitment for Alzheimer’s clinical trials.
Categorized in -
Recommendations To Address Key Recruitment Challenges of Alzheimer’s Disease Clinical Trials
An advisory panel of experts convened in 2020 to assess the critical challenges facing recruitment in Alzheimer’s clinical trials and develop a set of recommendations to overcome them.
-
Benzodiazepine Use and the Risk of Dementia
There is little evidence that older adults prescribed benzodiazepines—drugs commonly used to treat anxiety, insomnia and seizures—are at increased risk of developing dementia.
-
Benzodiazepines Don’t Increase Dementia Risks in Older Adults, USC Study Finds
There is little evidence that older adults prescribed benzodiazepines are at increased risk of developing dementia.
-
Access to Disease-Modifying Alzheimer’s Therapies: Addressing Possible Challenges Using Innovative Payment Models
Researchers use the Future Elderly Model to estimate potential benefits of disease-modifying therapies for Alzheimer disease.
Categorized in